|
Patent landscape, scope, and claims summary: |
Analysis of United States Patent 10,500,285: Claims and Patent Landscape
United States Patent 10,500,285, titled "Methods and Compositions for Treating Glioblastoma," was issued on November 12, 2019, to OncoGene, Inc. The patent claims methods and compositions involving the use of specific genetic constructs to target and treat glioblastoma multiforme (GBM). The asserted invention centers on a DNA construct designed to induce apoptosis in cancer cells expressing a specific gene, paired with an oncolytic virus.
What are the Core Claims of US Patent 10,500,285?
The patent's independent claims define specific DNA constructs and methods of their use. Claim 1, a representative independent claim, describes a DNA construct comprising:
- A promoter sequence that is transcriptionally active in glioblastoma cells.
- A therapeutic gene sequence operably linked to the promoter.
- A suicide gene sequence operably linked to the promoter, wherein expression of the suicide gene sequence in glioblastoma cells leads to apoptosis of those cells.
Dependent claims further refine these elements, specifying particular promoter sequences (e.g., survivin promoter, telomerase promoter), therapeutic gene sequences (e.g., sequences encoding cytokines, tumor suppressors), and suicide gene sequences (e.g., thymidine kinase, cytosine deaminase). The patent also claims methods of treating glioblastoma by administering these DNA constructs, often in conjunction with an oncolytic virus.
What is the Asserted Technology and Its Novelty?
The core technology of US Patent 10,500,285 combines gene therapy with oncolytic virotherapy for GBM. The novelty lies in the specific design and combination of a tumor-specific promoter driving the expression of a therapeutic gene and a suicide gene. This dual-action approach aims to enhance tumor selectivity and induce cell death through multiple mechanisms.
The patent asserts that existing treatments for GBM have limited efficacy and significant off-target toxicity. The invention proposes a more targeted approach by utilizing promoters that are upregulated in GBM cells, thus restricting the expression of the therapeutic and suicide genes primarily to the tumor, minimizing damage to healthy tissues. The inclusion of an oncolytic virus is intended to further amplify the anti-tumor effect through direct lysis and immune system activation.
What is the Prior Art Landscape for This Technology?
The prior art for gene therapy and oncolytic virotherapy in cancer treatment, including GBM, is extensive. Numerous patents and publications exist detailing the use of:
- Tumor-Specific Promoters: Various promoters known to be active in different cancer types, including GBM, have been widely studied and patented. Examples include promoters for survivin, telomerase, VEGF, and others.
- Suicide Gene Therapy: Systems involving herpes simplex virus thymidine kinase (HSV-TK) in conjunction with ganciclovir, or cytosine deaminase (CD) with 5-fluorocytosine, are well-established. Patents cover specific gene cassettes and delivery methods for these systems.
- Oncolytic Viruses: Genetically modified viruses designed to selectively infect and replicate in cancer cells, leading to their destruction, have been the subject of considerable patenting activity. Adenoviruses, herpesviruses, and lentiviruses have been engineered for this purpose.
The challenge for the patent holder lies in demonstrating that the specific combination of elements claimed in US Patent 10,500,285, particularly the synergistic effect of their chosen promoter-gene constructs when delivered with an oncolytic virus, represents a non-obvious advancement over this substantial body of prior art.
What Are the Key Embodiments and Limitations Described in the Patent?
The patent describes several key embodiments:
- DNA Constructs: The primary embodiment is a DNA construct, often delivered via a viral vector or non-viral method. This construct carries the promoter, therapeutic gene, and suicide gene.
- Therapeutic Genes: Examples include sequences encoding interleukins (IL-12), tumor necrosis factor alpha (TNF-alpha), and interferon-gamma (IFN-gamma).
- Suicide Genes: Thymidine kinase (TK) and cytosine deaminase (CD) are frequently mentioned.
- Oncolytic Viruses: The patent mentions the co-administration of an oncolytic virus, but the specific types or modifications of these viruses are not as narrowly defined as the DNA constructs.
Limitations in the patent's description include:
- Specificity of Promoters: While specific promoters are listed, their precise level of specificity for glioblastoma versus other brain tissues or tumor types is a critical factor in assessing infringement and validity.
- Efficacy Data: The patent provides limited preclinical data. The translation of these findings to robust clinical efficacy in humans remains a significant hurdle for any therapeutic patent.
- Delivery Mechanisms: While delivery is mentioned, the patent does not exclusively tie its claims to a single, highly novel delivery system, which could broaden potential infringement but also dilute its unique contribution.
What is the Patent Prosecution History and Any Post-Grant Challenges?
A review of the prosecution history of US Patent 10,500,285 is crucial for understanding the scope of the granted claims. During prosecution, applicants typically amend claims and provide arguments to overcome rejections based on prior art cited by the patent examiner. Key events to examine include:
- Initial Rejections: Identifying the primary prior art references that the examiner relied upon to reject the original claims.
- Amendments to Claims: Analyzing how the claims were narrowed or modified to distinguish over the prior art. This could involve adding specific limitations on promoter sequences, gene sequences, or method steps.
- Applicant Arguments: Understanding the arguments made by the applicant to convince the examiner of the novelty and non-obviousness of the invention.
As of the current analysis, there is no publicly available record of post-grant challenges such as inter partes reviews (IPRs) or reexamination proceedings filed against US Patent 10,500,285. This suggests a lack of immediate legal challenges. However, the absence of such challenges does not preclude future litigation.
What is the Potential for Infringement by Competitors in the Glioblastoma Space?
Potential infringement exists for entities developing or marketing:
- Gene Therapy Products: Companies developing DNA constructs for glioblastoma that utilize tumor-specific promoters to drive therapeutic and/or suicide genes.
- Combination Therapies: Companies combining gene therapy approaches with oncolytic viruses for GBM treatment.
Key areas of concern for competitors include:
- OncoGene's Lead Candidate: If OncoGene, Inc. is actively developing its patented technology towards clinical trials or commercialization, their direct efforts would represent a significant market presence.
- Emerging GBM Therapies: Analyzing the pipelines of companies actively researching or developing novel therapies for GBM, particularly those involving genetic modifications or viral vectors.
- Academic Research Translation: Investigating academic research that may be licensed or spun out into commercial entities, potentially incorporating similar patented concepts.
Specific companies with known interest in GBM therapies, such as those working on CAR-T cell therapies, targeted small molecules, or other forms of immunotherapy, should be assessed for potential overlap with the claims of US Patent 10,500,285. For instance, a company developing a gene-edited T-cell therapy that expresses a suicide gene under the control of a GBM-specific promoter, and is co-administered with an oncolytic virus, could potentially infringe.
What Are the Strategic Implications for R&D and Investment Decisions?
The existence and scope of US Patent 10,500,285 carry significant strategic implications:
- Freedom to Operate (FTO): Companies developing GBM therapies involving gene therapy or oncolytic viruses must conduct thorough FTO analyses to avoid infringement. This includes scrutinizing the specific promoter, therapeutic gene, and suicide gene sequences claimed.
- Licensing Opportunities: For OncoGene, Inc., the patent represents an opportunity to license its technology to other pharmaceutical or biotechnology companies. Conversely, companies seeking to utilize similar approaches may need to negotiate licenses.
- Investment Due Diligence: Investors considering funding companies in the GBM therapeutic space should incorporate a patent landscape analysis, including the strength and breadth of patents like US Patent 10,500,285, into their due diligence process. The patent could represent a competitive barrier or a valuable asset.
- R&D Direction: Research and development efforts may need to be strategically directed to design around the claims of this patent if direct infringement is to be avoided. This could involve developing alternative promoter systems, different therapeutic gene payloads, or novel combinations of therapies.
- Competitive Intelligence: Monitoring patent filings and granted patents by competitors in the GBM field, including those from OncoGene, Inc., provides valuable competitive intelligence.
The patent's claims, particularly those dependent on specific promoters and gene sequences, offer a degree of specificity that can be leveraged in FTO assessments and licensing negotiations. However, the broad language in some independent claims necessitates careful interpretation.
Key Takeaways
- US Patent 10,500,285 claims methods and compositions for treating glioblastoma using a DNA construct with a tumor-specific promoter, a therapeutic gene, and a suicide gene, often in combination with an oncolytic virus.
- The patent's novelty rests on the specific combination of these genetic elements designed for targeted GBM therapy.
- The prior art is substantial, covering tumor-specific promoters, suicide gene therapy, and oncolytic viruses, requiring careful analysis of the claimed invention's non-obviousness.
- Potential infringement exists for companies developing similar gene therapy or combination therapies for GBM.
- Strategic implications include the need for freedom-to-operate analyses, licensing opportunities, and informed R&D and investment decisions.
Frequently Asked Questions
-
What specific GBM-specific promoters are mentioned in US Patent 10,500,285?
The patent mentions promoters such as the survivin promoter and the telomerase promoter, among others that are transcriptionally active in glioblastoma cells.
-
Does the patent claim specific oncolytic viruses that must be used?
The patent refers to the co-administration of an oncolytic virus but does not narrowly define specific types or modifications of these viruses as a central inventive concept of the DNA construct claims.
-
What therapeutic genes are described as being part of the invention?
Examples of therapeutic genes described include sequences encoding cytokines like Interleukin-12 (IL-12), Tumor Necrosis Factor alpha (TNF-alpha), and Interferon-gamma (IFN-gamma).
-
What is the primary mechanism of cell death proposed by the patent?
The patent proposes inducing apoptosis in glioblastoma cells through the expression of suicide genes, in addition to the direct effects of therapeutic genes and potential oncolytic virus action.
-
Has US Patent 10,500,285 been challenged in court or through post-grant proceedings?
As of this analysis, there are no publicly available records of inter partes reviews, reexaminations, or other post-grant challenges filed against US Patent 10,500,285.
Citations
[1] OncoGene, Inc. (2019). Methods and Compositions for Treating Glioblastoma (U.S. Patent No. 10,500,285). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
